Finance

Weight-Loss Drugs for Children Surge as WHO Urges Caution

Explore why GLP-1 weight-loss drugs for children aged 8 to 11 are surging at NYU Langone's count, while the WHO warns that long-term evidence is still missing.

Farhan Khan's avatar
Farhan KhanStaff
4 min read

Key Takeaways

  • GLP-1 prescriptions for kids aged 8 to 11 are 310 times higher than in 2019, yet still a sliver of the children who qualify.
  • No GLP-1 drug is FDA-approved for under-12s, so doctors lean on off-label prescribing in severe cases.
  • The study's lead investigator worries less about the drugs than about why so many kids need them.
  • Children in higher-income communities are 55% more likely to get a prescription, so access is uneven.
  • The WHO says evidence is too thin to recommend these drugs for children under 10.
  • Nobody can yet say how long a child would need to stay on treatment.
A graphic of a steep upward arrow beside a child-sized pill bottle, showing the rise in GLP-1 prescriptions for children.
Kids' GLP-1 Prescriptions Surge

Imagine a pharmacy counter where the youngest customer is barely tall enough to see over it. That scene is getting less rare. A new NYU Langone study found that GLP-1 prescriptions for children aged 8 to 11 are 310 times higher than they were in 2019.

The drugs behind the surge, such as Wegovy, Saxenda and Zepbound, are not FDA-approved for kids under 12. Doctors can still prescribe them off-label in extreme cases, and more of them are doing exactly that.

Meanwhile, the World Health Organization is pulling the other way, saying the evidence simply isn't there for children under 10. Two big forces, one small patient. Let's get started.

Surging Childhood GLP-1 Prescriptions

Think of 2019 as a trickle and today as a tap turned wide open. NYU Langone found that GLP-1 prescriptions for kids aged 8 to 11 are now 310 times higher than they were back then.

The drugs are not FDA-approved for children under 12, but doctors may prescribe them off-label in extreme cases. Clinical guidelines also allow obesity treatment from age eight in certain situations, which gives physicians room to act.

But a jump that dramatic can mislead. Starting from almost nothing, any growth looks explosive. The real question is who is getting these prescriptions, and whether the pace should worry us or reassure us.

Sizing Up the Real Numbers

Percentages can make a molehill look like a mountain. Here, the mountain is real, but it sits beside a far bigger range.

The study counted 20,282 children who received GLP-1 drugs, mostly Wegovy. Set against roughly 3.3 million 8- to 11-year-olds with obesity, that is a sliver. Lead investigator Dr. Babak Orandi calls it a very small number, even as uptake accelerates.

So the story isn't a flood of kids on skinny jabs. It's a steep climb from a very low base, with most eligible children still untreated. Orandi says most who could benefit still aren't getting the drugs.

Understanding Who Gets Treated

These aren't casual prescriptions. Picture a child whose body is already sending warning flares before middle school.

The study found that 94% of the children prescribed GLP-1s had severe obesity, and about 65% had at least one related condition. Think high cholesterol, high blood pressure, sleep apnea, pre-diabetes or fatty liver disease. For these kids, doctors see a tool for blood sugar and long-term risk.

Yet Orandi's sharpest point isn't about the drugs at all. He is less concerned about uptake than about the underlying factors driving the trend, because so many children need treatment in the first place.

Spotting Access Gaps

A miracle drug that only some families can reach isn't quite a miracle. It's a privilege with a prescription pad.

Children in higher-income communities were 55% more likely to be prescribed these medicines, a sign of emerging disparities in access. Study co-author Allan Massie argues the treatments should reach more than those who have health insurance and can afford pediatric clinics.

The irony stings. Obesity and its complications don't respect income brackets, yet the treatment does, and that tilts the field before anyone steps onto it.

Weighing Long-Term Unknowns

Giving a child a drug that reshapes appetite is like repainting a house while the foundation is still setting. Nobody knows yet how it all dries.

Pediatrician Dan Cooper worries about growth, bones and puberty, noting there are no long-term studies in teens, so young patients are practically research participants. The WHO echoes the caution, recommending against these drugs for children under 10 because evidence is lacking.

WHO nutrition unit head Laurence Grummer-Strawn asks the question nobody can answer: when does it stop? Without evidence that treatment can be temporary, the answer remains a blank.

Long Story Short

Strip away the headlines and the picture is oddly split. The prescriptions are climbing fast, yet they reach only a tiny fraction of the children who are eligible. The WHO, for its part, wants children under 10 on healthy eating and exercise rather than medication. So what should a parent or policymaker take from it? Ask hard questions about the long game. Researchers still can't say how long these drugs keep working, what long-term side effects they carry, or whether a child would ever be able to stop. Pair any prescription with the supervised lifestyle support the WHO emphasizes, and push for access that doesn't depend on your zip code. The outlook is a race between evidence and demand. Long-term safety monitoring has to catch up with the prescriptions, because for the families in this study, the stakes are measured in decades, not months.

Finsights

From signal to strategy — insights that drive better decisions.

Must Consider

Things to keep an eye on — the factors that could influence your takeaway from this story/topic

Core considerations

A 310-fold rise sounds like a stampede, but the study counts 20,282 children against about 3.3 million with obesity. The headline number says more about how little treatment existed in 2019 than about reckless prescribing. The real limitation is time: the drugs are being used in critical periods of growth, and nobody has long-term data. The WHO's caution and the NYU team's concern about unequal access pull in opposite directions, and both can be right.

Key elements to understand

Our Two Cents

Our no-nonsense take on the trends shaping the market — what you should know

Our take

Both camps have a point, and that's what makes this uncomfortable. For a child with severe obesity and early complications, waiting for perfect evidence carries its own risk. For a healthy-ish eight-year-old, a drug with no long-term track record is a big bet. The smartest path is careful, supervised use for the children who are most at risk, with the follow-up data collected as we go. The downside of leaning on medication alone is that it can sideline the food and activity habits that no pill replaces.

Trends that shape the narrative

Similar Reads

Latest articles on Finance